Viking Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Viking Therapeutic (VKTX) PT Lowered to $20 at Maxim Group, Remains Bullish
March 14, 2019 7:35 AM EDTMaxim Group analyst Jason McCarthy lowered the price target on Viking Therapeutic (NASDAQ: VKTX) to $20.00 (from $28.00) while maintaining a Buy rating following Q4.
Viking reported 4Q18 with a net loss of ($5.6M) and ended the year with $302M in cash on the balance sheet. Over the course of 2018, the NASH space continued to deliver positive data, in... MoreViking Therapeutics (VKTX) Tops Q4 EPS by 3c
March 13, 2019 4:12 PM EDTViking Therapeutics (NASDAQ: VKTX) reported Q4 EPS of ($0.07), $0.03 better than the analyst estimate of ($0.10).
"The past year has been a transformative period for Viking, and we are excited to continue this momentum in 2019," stated Brian Lian, Ph.D., chief executive officer of Viking Therapeutics. "We were... More
